CORAL GABLES, FL / ACCESSWIRE / February 25, 2019 / The future success of the healthcare stock market will be determined by whether companies in the industry are aptly prepared to meet the growing demands for better healthcare. Millions of people around the world are without access to qualitative care options, and as harmful diseases are discovered, the need for better treatment options becomes exponentially more necessary. Typically, every so often, humanity takes a leap forward thanks to a series of technological advancements or scientific discoveries. The most recent change has been a shift in public opinion towards supporting cannabis as a means of treatment. Medical professionals are now advocating for legislation in favor of legalizing marijuana because of the list of health benefits afforded to those who use medicinal cannabis. If these trends continue, companies in the healthcare industry could see an influx of investors looking for lucrative opportunities. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Titan Pharmaceuticals Inc (TTNP), Aurora Cannabis Inc (NYSE: ACB; TSX: ACB), and Actinium Pharmaceuticals Inc (NYSE American: ATNM) represent four healthcare companies focused on improving the quality of life for their patients.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which has risen to the top of the field because of their unrelenting determination to invest and develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies. Whereas other companies in healthcare remain stagnant due to goal-related issues, Premier's patient-centric focus has allowed for a consistent motivator for operating at optimal capacity.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) successfully acquired Cloud Practice Inc., a healthcare technology company that provides cloud-based electronic medical records software applications for physicians throughout Canada. Cloud Practice's suite of products includes Juno EMR, a cloud-based EMR solution; ClinicAid, a medical billing software; and MyHealthAccess, an online patient portal. With this acquisition, Premier now has a collective ecosystem of over 3,000,000 active patients and 287 primary care clinics.
Premier Health Group (OTC:PHGRF) (CSE:PHGI)'s management team is working closely with the development team at Cloud Practice to build an integrated patient portal that will include a telemedicine component - a beta version of the app will be available by end of Q2. With the app, Premier Health is aiming to remove the accessibility bottlenecks that exist within healthcare systems. The patient will have the ability to see their physician, access their charts & lab results, chat securely with clinical staff, reorder prescriptions and share remote health monitoring data with their doctor - all at their fingertips.
Titan Pharmaceuticals Inc (TTNP) today announced the execution of a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment with Probuphine (buprenorphine) implant, Titan's unique six-month maintenance treatment for opioid use disorder (OUD) in eligible patients.
Following the announcement, Dane Hallberg, Chief Commercial Officer for Titan Pharmaceuticals, said, ''we are excited to expand our specialty pharmacy network for Probuphine to include such a nationally-recognized leader as AllianceRx Walgreens Prime. AllianceRx Walgreens Prime has excellent relationships with third-party payors and a network of fulfillment sites that spans the entire country.''
Aurora Cannabis Inc (ACB) found itself in headlines today when the Company announced that both its Aurora Sky and MedReleaf Bradford facilities are now fully licensed by Health Canada for the production and sale of cannabis and cannabis derivative products.
Terry Booth, Chief Executive Officer of Aurora, commented, ''current production at Aurora Sky, with recent harvests exceeding target yields, validates our production philosophy and our investment in high-tech, highly automated facilities. MedReleaf Bradford employs best practices identified during the integration of the Aurora and MedReleaf organizations, and is consistently delivering exceptional yields and high-quality product that has resonated well in both the medical and consumer markets.''
Actinium Pharmaceuticals Inc (ATNM) today announced the reporting of new data from the Company's ongoing pivotal Phase 3 trial for lomab-B. Per the details of the results, all patients who received Iomab-B, received a BMT or Bone Marrow Transplant with 100% (28/28) of patients achieving engraftment and Donor Chimerism. The new data indicated that 92% (26/28) of these patients achieved Full Donor Chimerism prior to day 100, which is defined as at least 95% of donor cells being engrafted in the recipient.
Dr. Mark Berger, Chief Medical Officer for Actinium, commented, ''we are excited that data from the SIERRA trial continue to demonstrate strong engraftment, particularly in this patient population who have limited access to BMT, which is the only curative treatment option, with current chemotherapy-based conditioning approaches"
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: